ImmuPharma plc's latest marketcap:
As of 08/02/2025, ImmuPharma plc's market capitalization has reached $13.8 M. According to our data, ImmuPharma plc is the 38915th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 13.8 M |
| Revenue (ttm) | -92,891.56 |
| Net Income (ttm) | -3,297,589.97 |
| Shares Out | 499.72 M |
| EPS (ttm) | -0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/05/2025 |
ImmuPharma plc's yearly market capitalization.
| Date | Market Cap(£) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/02/2025 | £10.39 M | $13.8 M | 107.14% | 38915 |
| 12/31/2024 | £5.02 M | $6.28 M | -27.71% | 40032 |
| 12/29/2023 | £6.94 M | $8.84 M | 13.16% | 37580 |
| 12/30/2022 | £6.13 M | $7.42 M | -62.85% | 37006 |
| 12/31/2021 | £16.51 M | $22.32 M | -50.56% | 32172 |
| 12/31/2020 | £33.4 M | $45.66 M | 24.75% | 25246 |
| 12/31/2019 | £26.78 M | $35.51 M | 63.4% | 23718 |
| 12/31/2018 | £16.39 M | $20.89 M | -92.73% | 25247 |
| 12/29/2017 | £225.29 M | $304.16 M | 247.6% | 12823 |
| 12/30/2016 | £64.81 M | $80.02 M | 143.78% | 16999 |
Company Profile
About ImmuPharma plc
ImmuPharma plc is a biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics. Headquartered in London, United Kingdom, the company focuses on innovative treatments for autoimmunity, inflammation, and anti-infective therapies.
Key Product Candidates
- P140 (Lupuzor) – A peptide technology platform in Phase III clinical trials for systemic lupus erythematosus (SLE). Also in Phase II trials for chronic inflammatory demyelinating polyneuropathy (CIDP), with potential applications in asthma, gout, periodontitis, and inflammatory bowel disease (IBD).
- BioAMB – A peptide-based drug targeting serious fungal infections like aspergillosis.
- BioCin – A vancomycin-based treatment for anti-infection therapy.
Strategic Collaborations
ImmuPharma has established key partnerships to advance its research:
- Collaboration with Centre National de la Recherche Scientifique (CNRS) for the development of the P140 platform.
- License and development agreement with Avion Pharmaceuticals LLC.
Founded: 1999
Headquarters: London, United Kingdom
Frequently Asked Questions
-
What is ImmuPharma plc's (AIM-IMM) current market cap?As of 08/02/2025, ImmuPharma plc (including the parent company, if applicable) has an estimated market capitalization of $13.8 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does ImmuPharma plc (AIM-IMM) rank globally by market cap?ImmuPharma plc global market capitalization ranking is approximately 38915 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.